NET PROFIT (x1000 EUR)
EMPLOYEES
Annexin Pharmaceuticals AB (publ)
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
0
|
0
|
182 |
| Earnings before taxes |
-3,970
|
-3,660
|
-5,099 |
| EBITDA |
-3,981
|
-3,659
|
-5,010 |
| Total assets |
2,412
|
3,296
|
5,161 |
| Current assets |
2,245
|
3,024
|
4,959 |
| Current liabilities |
716
|
586
|
592 |
| Equity capital |
1,696
|
2,710
|
4,569 |
| - share capital |
517
|
230
|
2,684 |
| Employees (average) |
4
|
5
|
5 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
70.3%
|
82.2%
|
88.5% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-164.6%
|
-111.0%
|
-95.3% |
| Current ratio |
313.5%
|
516.0%
|
837.7% |
| Return on equity (ROE) |
-234.1%
|
-135.1%
|
-111.6% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
-1
|
0
|
1 |
| Chg. No. of employees % |
-20%
|
0%
|
25% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.